https://2022.boabangkok.com/wp-content/uploads/2022/08/Doctor-Consulting-With-A-Patient-Sample-Video.mp4

Stada https://2022.boabangkok.com/wp-content/uploads/2022/08/Doctor-Consulting-With-A-Patient-Sample-Video.mp4 สอบถามข้อมูลเพิ่มเติมได้ที่Line OA STADA Thailand https://2022.boabangkok.com/wp-content/uploads/2022/08/Doctor-Consulting-With-A-Patient-Sample-Video.mp4

Abstract 9000 Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. Background: FDA-approved…

Takeda https://2022.boabangkok.com/wp-content/uploads/2022/08/Doctor-Consulting-With-A-Patient-Sample-Video.mp4

Abstract LBA2 Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing…

Abstract LBA4011 Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. Background: Pancreatic cancer is…

Mundipharma https://2022.boabangkok.com/wp-content/uploads/2022/08/placeholder-16.png

Abstract LBA9500 Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study. Background: In previous analyses of the phase 3,…

Abstract 5000 TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603). Background: We previously reported that…

Abstract 3503 Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer Background: Continuous anti-EGFR-based FOLFIRI is a first-line standard of care in pts…